Kiyoi, Hitoshi

Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study

Kobayashi, T., Iwama, S., Yasuda, Y., Okada, N., Tsunekawa, T., Onoue, T., Takagi, H., Hagiwara, D., Ito, Y., Morishita, Y., et al. (2018) · Journal of the Endocrine Society

Cancer Immunotherapy and BiomarkersThyroid Disorders and Treatments

Cited by 203

Histone deacetylase inhibitors are the potent inducer/enhancer of differentiation in acute myeloid leukemia: a new approach to anti-leukemia therapy.

Kosugi, H., Towatari, M., Hatano, S., Kitamura, K., Kiyoi, H., Kinoshita, T., Tanimoto, M., Murate, T., Kawashima, K., Saito, H., et al. (1999) · Leukemia

Acute Myeloid Leukemia ResearchHistone Deacetylase Inhibitors Research

Cited by 150

Biology and management of primary effusion lymphoma

Shimada, K., Hayakawa, F., & Kiyoi, H. (2018) · Blood

Viral-associated cancers and disordersLymphoma Diagnosis and Treatment

Cited by 103

Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies: a prospective study

Okada, N., Iwama, S., Okuji, T., Kobayashi, T., Yasuda, Y., Wada, E., Onoue, T., Goto, M., Sugiyama, M., Tsunekawa, T., et al. (2020) · British Journal of Cancer

Cancer Immunotherapy and BiomarkersThyroid Disorders and Treatments

Cited by 78

Exosomes secreted from cancer-associated fibroblasts elicit anti-pyrimidine drug resistance through modulation of its transporter in malignant lymphoma

Kunou, S., Shimada, K., Takai, M., Sakamoto, A., Aoki, T., Hikita, T., Kagaya, Y., Iwamoto, E., Sanada, M., Shimada, S., et al. (2021) · Oncogene

Extracellular vesicles in diseaseMicroRNA in disease regulation

Cited by 62

Prognostic analysis of aberrant somatic hypermutation of RhoH gene in diffuse large B cell lymphoma

Hiraga, J., Katsumi, A., Iwasaki, T., Abe, A., Kiyoi, H., Matsushita, T., Kinoshita, T., & Naoe, T. (2007) · Leukemia

Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research

Cited by 23

Nilotinib vs dasatinib in achieving MR4.5 for de novo chronic myeloid leukemia: the randomized JALSG CML212 study

Matsumura, I., Ohtake, S., Atsuta, Y., Kurata, M., Minami, Y., Takahashi, N., Nakaseko, C., Iriyama, N., Fujimaki, K., Kakihana, K., et al. (2024) · Blood Advances

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 21